ArticleRegenerative biomaterials2026
Iron-quercetin nanocomplex preconditioning reprograms the mesenchymal stem cell secretome to drive angiogenic, fibroblast and immunoregulatory wound repair.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic wounds remain a major clinical challenge characterized by impaired angiogenesis, persistent inflammation and dysfunctional stromal responses. Increasing evidence indicates that the therapeutic effects of mesenchymal stem cells (MSCs) are largely mediated by paracrine signaling, making MSC-derived secretomes promising cell-free regenerative therapies. However, conventional culture conditions do not fully harness MSC plasticity to enhance secretion of pro-regenerative factors. In this study, we investigated an iron-quercetin nanocomplex (IronQ) as a biocompatible preconditioning strategy to improve the therapeutic secretome of adipose-derived MSCs (ADSCs). IronQ priming preserved cell viability and phenotypic integrity while allowing efficient intracellular uptake. Transcriptomic analysis demonstrated coordinated ADSC reprogramming, with enrichment of pathways related to extracellular matrix organization, angiogenesis, immune regulation, iron homeostasis and tissue morphogenesis. Consistently, IronQ-preconditioned ADSC secretomes showed increased levels of key trophic and immunomodulatory factors, including VEGF-A, HGF, EGF, FGF-2, PDGF-AA, SDF-1α, G-CSF, CCL-2 and IL-10. Functionally, the conditioned secretome enhanced endothelial proliferation and tube formation, promoted fibroblast migration and activation, and induced macrophage polarization toward a reparative M2 phenotype
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.